The BioBlog

June 8, 2011

No Comments

No comments yet.

RSS feed for comments on this post.

Sorry, the comment form is closed at this time.

•  

  May 2012

  M	T	W	T	F	S	S
  « Aug
  	1	2	3	4	5	6
  7	8	9	10	11	12	13
  14	15	16	17	18	19	20
  21	22	23	24	25	26	27
  28	29	30	31

• Translate this Page
  
  Select LanguageAfrikaansAlbanianArabicArmenianAzerbaijaniBasqueBelarusianBulgarianCatalanChinese (Simplified)Chinese (Traditional)CroatianCzechDanishDutchEnglishEstonianFilipinoFinnishFrenchGalicianGeorgianGermanGreekHaitian CreoleHebrewHindiHungarianIcelandicIndonesianIrishItalianJapaneseKoreanLatvianLithuanianMacedonianMalayMalteseNorwegianPersianPolishPortugueseRomanianRussianSerbianSlovakSlovenianSpanishSwahiliSwedishThaiTurkishUkrainianUrduVietnameseWelshYiddish
• • Stay updated
  • RSS feed
• Tags
  • acquisition
  • Avinza
  • biotech
  • Celebrex
  • Deloitte
  • drug delivery
  • drug development
  • drug discovery
  • Embeda
  • emerging markets
  • Exubra
  • Flector Patch
  • generics
  • GlaxoSmithKline (GSK)
  • GSK
  • J&J
  • John Curd
  • Johnson & Johnson (J&J)
  • King Pharmaceutical
  • King Pharmaceuticals
  • Lipitor
  • Lyrica
  • M&A
  • Novacea
  • Novartis
  • patent
  • patent cliff
  • patient cliff
  • Pfizer
  • Pharmaceutical
  • pharmaceutical sales
  • Pipeline
  • Pricing
  • Profitability
  • Roche
  • Torcetrapib
  • Wyeth
• Archives
  • August 2011
  • June 2011
  • October 2010
• Advertisement
• Stock Quotes
• Other Important Industry Blogs
  Cafe Pharma
  PharmaGossip
  Pharmalot
  Pharma Reform
  Pharma Marketing Blog
  Eye on FDA
  
• About the Authors
  • Judy Feuerbach
  • Ted Feuerbach